BRIEF — Certa to nab A$22 million public and industry funding

Certa Therapeutics has become the largest recipient of support to date from Australia’s Federal Government’s Biomedical Translation Fund (BTF).

The company, which has laboratories based at the University of Melbourne, is to receive A$22 million ($17 million) from BTF on the promise that it could revolutionize the way kidney disease is treated.

BTF consists of equal parts Commonwealth and industry funding, and is managed by private sector fund managers, who make investments in Australian biomedical ideas with great potential.

Brandon Capital Partners will invest into Certa to help commercialize its kidney disease treatment, providing Australian patients with direct access to the medicine through clinical trials while giving taxpayers an opportunity to maximize their investment.